Portugal HIV Therapeutics Market Analysis Report [2022-30]

Portugal HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Portugal HIV therapeutics market will reach a value of $xx Mn from $41.28 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Hovione, Bial, and Bluepharma. The market is driven by government policies and initiatives for the management of HIV infections in the country. The HIV therapeutics market in Portugal is segmented by type, product, geography, end user, and distribution channel.

ID: IN10PTPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Portugal AUTHOR: Dr. Vishwa Modhia

Buy Now

Portugal HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Portugal HIV therapeutics market will reach a value of $xx Mn from $41.28 Mn in 2022, growing at a CAGR of xx% during 2022-2030.

Portugal is a country in southwestern Europe that is located on the Iberian Peninsula and is bordered by Spain and the Atlantic Ocean. According to the most recent WHO data, HIV/AIDS-related deaths in Portugal reached 500 in 2020. With an age-adjusted death rate of 2.21 per 100,000 people, Portugal ranks 102nd in the world.

Portugal's adult HIV/AIDS prevalence was 0.5 percent in 2020, ranking 66th globally with 42,000 HIV cases. In 2019, Portugal spent 10.6 percent of its GDP on healthcare. Pharmaceuticals and consumables accounted for 14.6 percent of the Portuguese government's healthcare budget. ABRAO - Associaço de Apoio a Pessoas com, LPCS - Liga Portuguesa Contra a SIDA, Associaço Existências, and other organizations work in the HIV/AIDS field in Portugal.

Market Dynamics

Market Growth Drivers

The Portuguese government's strong commitment to providing universal access to healthcare services and medications, including HIV therapeutics. Collaboration among pharmaceutical companies, healthcare providers, and patient advocacy organizations to improve HIV care in Portugal. These elements may influence the demand for HIV therapeutics in Portugal.

Market Restraints

Stigma and discrimination continue to affect HIV-positive people in Portugal, discouraging some from seeking treatment or disclosing their status. The difficulties in providing healthcare and medications to marginalized and vulnerable populations, such as drug users and migrants, who are at a higher risk of HIV infection.

Competitive Landscape

Key Players

Bluepharma (PRT)
Bial (PRT)
Hovione (PRT)
Tecnimede (PRT)
Azevedos Indústria (PRT)
Gilead Sciences
AbbVie
Roche

Healthcare Regulations and Reimbursement Policies

The Portuguese National Authority of Medicines and Health Products (INFARMED - Autoridade Nacional do Medicamento e Produtos de Sade) regulates HIV therapeutics in Portugal. INFARMED is in charge of evaluating and approving new drugs, as well as ensuring their safety and efficacy and meet quality standards. HIV medications must go through extensive testing and clinical trials before they can be used in Portugal. They are closely monitored for any adverse effects or drug interactions once they have been approved. To ensure patient safety and appropriate drug use, healthcare professionals must follow strict guidelines when prescribing and dispensing HIV medications.

HIV therapeutics are generally covered by the national healthcare system in Portugal, which provides universal access to healthcare services and medications. The Portuguese National Health Service reimburses HIV medications, which means that patients pay only a portion of the cost of the medication, with the rest covered by the government. Patients must be registered with a Portuguese general practitioner and have a prescription from a licensed healthcare professional to be eligible for reimbursement. The level of reimbursement may vary depending on the medication and the patient's health condition.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.